^
    9ms
    BGB-A317-3111-10188-101: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov)
    P1/2, N=126, Recruiting, BeiGene | Trial completion date: Nov 2025 --> Feb 2025
    Trial completion date • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    paclitaxel • Tevimbra (tislelizumab) • Brukinsa (zanubrutinib) • BGB-10188
    almost2years
    BGB-A317-3111-10188-101: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov)
    P1/2, N=150, Recruiting, BeiGene | Trial completion date: Apr 2025 --> Nov 2025
    Trial completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    paclitaxel • Tevimbra (tislelizumab) • Brukinsa (zanubrutinib) • BGB-10188
    2years
    PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. (PubMed, Cancers (Basel))
    The dual PI3Kδ/γ inhibitor duvelisib is approved for use in CLL patients but with similar toxicities to idelalisib. Umbralisib, a highly selective inhibitor of PI3Kδ and casein kinase-1ε (CK1ε), was found to be efficient and safe in monotherapy and in combination regimens in phase 3 trials in patients with CLL. Novel PI3Kis are under evaluation in early phase clinical trials. In this paper we present the mechanism of action, efficacy and toxicities of PI3Ki approved in the treatment of CLL and developed in clinical trials.
    Review • Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IGH (Immunoglobulin Heavy Locus) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    Aliqopa (copanlisib) • Zydelig (idelalisib) • Copiktra (duvelisib) • Ukoniq (umbralisib) • parsaclisib (INCB50465) • BGB-10188 • zandelisib (ME-401)
    4years
    Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov)
    P1/2, N=150, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab) • Brukinsa (zanubrutinib) • BGB-10188
    4years
    Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, BeiGene
    Clinical • New P1/2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab) • Brukinsa (zanubrutinib) • BGB-10188